The main objective is to createawareness and to assess the socio-demographic factors and BMI among pre-clinical students of UniKL RCMP towards overweight and obesity and to determine the correlation between the knowledge, attitude, and practice. A cross-sectional research was conducted among studentsusing questionnaire. All the questions in the questionnaire were then computed as the variables of thestudy. Respondents of year 2 score moderately in which male tends to score higher (n=30) than female (n=27) towards awareness of overweight and obesity. Besides, generally respondents with high household income (>RM9000) scored more awareness towards overweight and obesity. Furthermore, when taking hometown setting as a factor, respondent who lives in urban site tend to score higher (n=28) than the other two regions. In year 1 students,the data showed that female had a better knowledge, attitude and practice than male based on gender. Medium income (RM4000-9000) respondent have a better awareness than high and low income. Lastly, respondent who lives in urban site have a better awareness towards overweight and obesity compared to two other regions. In conclusion to the study conducted, it is found that femaleshave more awarenesswhen compared with malestowards overweight and obesity.The suburban people have higher score in practiceto overcome overweight and obesity but lower understanding than other regions. Thus,there is no significant correlation between gender, household income and region on awareness towards overweight and obesity. However,there were noticeable differences among the three individual variables.

The novel coronavirus disease 2019 (COVID-19) has reached its pandemic scale within a short period of its first case reported in Wuhan, China in December 2019, leading to a great economic crisis all over the world. As of today, there is no clinically approved antiviral drug available for the treatment of COVID-19. Tocilizumab, a humanized monoclonal antibody against the interleukin-6 (IL-6) receptor, clinically approved for the treatment of rheumatoid arthritis, is one such drug used to manage the COVID-19 symptoms. The current study reviews the effectiveness of Tocilizumab as a treatment option for COVID-19. Research findings on Tocilizumab are effective in COVID-19 patients with the risk of cytokine storm and further complications. Nevertheless, this review also recommends further investigation on the effectiveness of this drug with a large group of patients for more accuracy in results with COVID 19 patients.